Hansen H H, Mikkelsen J D
Department of Neurobiology, H. Lundbeck A/S, Valby-Copenhagen, Denmark.
Eur J Pharmacol. 1998 Jul 10;352(2-3):307-15. doi: 10.1016/s0014-2999(98)00349-5.
Chronic administration of clomipramine or other serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors to neonatal rats produces behaviours that resemble a depressive state in the adult animal, and this model is therefore regarded as a putative animal model of depression. Alterations in the activity of the central 5-HT system are important in understanding the pathophysiology of depression, and therefore, we examined whether this model was associated with changes in the expression of 5-HT1A receptor, 5-HT1B receptor, and 5-HT transporter mRNA in the dorsal raphe nucleus and the hippocampus. Wistar rats were injected twice daily with the serotonin reuptake inhibitors clomipramine and 5-chloro-1-[3-(dimethylamino)propyl]-1-(4-fluoro-phenyl)-1,3-dihydroi so-benzofurane, hydrochloride (code Lu 10-134-C) at doses of 15 mg kg(-1) or vehicle i.p. from postnatal day 8 for 14 days. Groups of rats (n = 10) were either killed the day after the last injection or left undisturbed for 69 days before they were killed. The expression of 5-HT transporter, 5-HT1A receptor, and 5-HT1B receptor mRNA was examined in the dorsal raphe nucleus and in the CA1 of the hippocampus by means of quantitative in situ hybridisation histochemistry. Both compounds resulted in an increase in 5-HT transporter mRNA expression (40% more than vehicle) in the dorsal raphe nucleus the day after the last injection (postnatal day 22). A small but significant increase in 5-HT1B receptor mRNA expression in the CA1 was seen after clomipramine, but not after Lu 10-134-C, probably reflecting clomipramine's affinity for both the 5-HT and noradrenaline transporters as well as for a number of monoamine receptor sites. Levels of 5-HT1A receptor mRNA were unchanged. In contrast, 5-HT transporter mRNA expression in the dorsal raphe nucleus was significantly decreased in the adult after neonatal treatment with either of the two drugs compared to vehicle. No changes in 5-HT1A receptor and 5-HT1B receptor mRNA expression were observed in any of the regions examined in these animals. The results show that the persistent depressive behaviour previously shown in this model is also associated with changes in the expression of 5-HT transporter mRNA. This long-term alteration in gene expression may result from disturbances in 5-HT neurotransmission in the brain of the neonatal animals.
对新生大鼠长期给予氯米帕明或其他血清素(5-羟色胺,5-HT)再摄取抑制剂会产生类似于成年动物抑郁状态的行为,因此该模型被视为一种假定的抑郁症动物模型。中枢5-HT系统活性的改变对于理解抑郁症的病理生理学很重要,因此,我们研究了该模型是否与中缝背核和海马体中5-HT1A受体、5-HT1B受体及5-HT转运体mRNA表达的变化有关。从出生后第8天起,将Wistar大鼠每天腹腔注射两次血清素再摄取抑制剂氯米帕明和5-氯-1-[3-(二甲氨基)丙基]-1-(4-氟苯基)-1,3-二氢异苯并呋喃盐酸盐(代号Lu 10-134-C),剂量为15 mg·kg⁻¹,或注射溶剂,持续14天。在最后一次注射后的第二天处死一组大鼠(n = 10),或在不进行处理的情况下饲养69天后处死。通过定量原位杂交组织化学法检测中缝背核和海马体CA1区中5-HT转运体、5-HT1A受体及5-HT1B受体mRNA的表达。在最后一次注射后的第二天(出生后第22天),两种化合物均导致中缝背核中5-HT转运体mRNA表达增加(比溶剂组多40%)。氯米帕明处理后,CA1区5-HT1B受体mRNA表达有小幅但显著的增加,而Lu 10-134-C处理后则没有,这可能反映了氯米帕明对5-HT和去甲肾上腺素转运体以及多个单胺受体位点的亲和力。5-HT1A受体mRNA水平未发生变化。相比之下,与溶剂组相比,新生期用这两种药物之一处理后的成年大鼠中缝背核中5-HT转运体mRNA表达显著降低。在这些动物的任何检测区域中,均未观察到5-HT1A受体和5-HT1B受体mRNA表达的变化。结果表明,该模型中先前显示的持续性抑郁行为也与5-HT转运体mRNA表达的变化有关。这种基因表达的长期改变可能是由于新生动物大脑中5-HT神经传递紊乱所致。